Incyte Corp at Citi Global Healthcare Conference Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: David Lebowitz - Citi - Analyst : Thank you very much for that. Start with Jakafi. It's been on the market for 13 years. It's on for myelofibrosis, it's on for PV. Could you tell us how the drug has been able to maintain such strong consistent growth for such a long time despite the entrance -- the attempted entrance of new competitors? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 03, 2024 / 1:00PM, INCY.OQ - Incyte Corp at Citi Global Healthcare Conference

Question: David Lebowitz - Citi - Analyst : Thank you. Now earlier this year, there was a little slowing growth in Jakafi. And of course, in the third quarter this year it really picked up again and it was growing pretty back in the double digits. Could you tell us about what factors played into the earlier growth? What factors are pulling into the more recent growth and how we should think about that into fourth quarter and into 2025?

Question: David Lebowitz - Citi - Analyst : Thank you. Now, GSK launched OJJAARA. Has that had much effect?

Question: David Lebowitz - Citi - Analyst : Now you've been developing an extended release once-daily version, and it was originally placed in front of the FDA. And the FDA sent it back. And you reformulated, and there will be data for the next version coming up in the first half of this year. Could you just run us through a little what happened with the original formulation, how is the new formulation different and what we expect to see in the first half of 2025?

Question: David Lebowitz - Citi - Analyst : When thinking in terms of pricing a once-daily formulation, would you expect to price at parity given that the cliff is coming up in two years? Or would you consider applying some premium just because it's a once daily versus twice at this point? And can you actually do that, given it is equivalence technically?

Question: David Lebowitz - Citi - Analyst : How easy do you think it will be to transition patients? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 03, 2024 / 1:00PM, INCY.OQ - Incyte Corp at Citi Global Healthcare Conference

Question: David Lebowitz - Citi - Analyst : Now, of course, a once-daily plays into the strategy of some of the follow-on assets. Could you tell us about the LIMBER programs and the various drugs being developed over there?

Question: David Lebowitz - Citi - Analyst : Sure. Start with the BET inhibitor. Can you tell us about the target, as far as what makes it an attractive target? And what else is in development? How is that dynamic setting up? What do you need to achieve?

Question: David Lebowitz - Citi - Analyst : Where do you ultimately be -- what population do you see it being most optimal if it were to reach market?

Question: David Lebowitz - Citi - Analyst : And just as a little bit of a preview, what do you expect to show next week?

Question: David Lebowitz - Citi - Analyst : So let's jump over to CALR. What is CALR? It's different than the other mechanisms and its little focus on a specific population. Can you run us through the mechanism of that? What makes it attractive?

Question: David Lebowitz - Citi - Analyst : Very helpful. How are the -- this specific cohort of patients, what is their prognosis at present relative to other MF patients? And I mean, obviously, this could stand to improve them further.

Question: David Lebowitz - Citi - Analyst : Now let's move on to the JAK2. Could you tell us about that molecule and how this fits in?

Question: David Lebowitz - Citi - Analyst : What should we expect to see from healthy patient data and the data next year? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 03, 2024 / 1:00PM, INCY.OQ - Incyte Corp at Citi Global Healthcare Conference

Question: David Lebowitz - Citi - Analyst : Let's jump over to graft-versus-host disease, recent approval. Could you tell us about the market and how axatilimab fits in?

Question: David Lebowitz - Citi - Analyst : Got it. And how does this impact Jakafi in that population as well?

Question: David Lebowitz - Citi - Analyst : If we jump to a different part of the business, Opzelura, povorcitinib. Clearly Opzelura has been ramping in AD and it's got a submission for pediatric underway. There's the vitiligo. How do you see one of these -- one therapy versus the other? And ultimately, could you run us through the upcoming data we have for expanding the opportunity?

Question: David Lebowitz - Citi - Analyst : Ultimately how do you see povorcitinib and Opzelura when they're in the same diseases being used?

Question: David Lebowitz - Citi - Analyst : Excellent. We have reached the end of our time here. Thank you so much for being with us, and we'll chat again soon.